dasatinib

Dasatinib is a highly potent dual Src/Abl inhibitor. It inhibits most mutations with the exception of the T315i mutation. The results of CCyR and MMR are similar to nilotinib. When this inhibitor was employed as first-line treatment, the responses were deeper, faster and superior to imatinib. The major side effects of this TKI inhibitor are thrombocytopenia, pleural effusion and more rarely, pulmonary complications.